CSIMarket
 
Jaguar Health inc   (JAGX)
Other Ticker:  
 
 
Price: $0.0700 $-0.01 -6.791%
Day's High: $0.0808 Week Perf: -1.96 %
Day's Low: $ 0.07 30 Day Perf: -13.69 %
Volume (M): 29,435 52 Wk High: $ 1.27
Volume (M$): $ 2,060 52 Wk Avg: $0.40
Open: $0.07 52 Wk Low: $0.05



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 21
 Employees -
 Revenues (TTM) (Millions $) 11
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 2

Jaguar Health Inc
Jaguar Health Inc is a pharmaceutical company that focuses on the development and commercialization of natural, plant-based medicines. The company primarily develops therapeutic products derived from the Croton lechleri tree. Its flagship product is Mytesi, an FDA-approved drug used for the symptomatic relief of noninfectious diarrhea in adults living with HIV/AIDS. Jaguar Health also explores potential uses of the Croton lechleri tree in the treatment of other conditions such as cancer and inflammatory bowel disease. The company aims to provide innovative and effective treatments for various diseases through its natural product pipeline.


   Company Address: 200 Pine Street, Suite 400 San Francisco 94104 CA
   Company Phone Number: 371-8300   Stock Exchange / Ticker: NASDAQ JAGX
   JAGX is expected to report next financial results on March 23, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Jaguar Health Inc

Jaguar Health Inc Struggles with Weak Sales, Facing Shortfall in the Third Quarter of 2023

Jaguar Health Inc, a pharmaceutical company focused on developing natural-based therapies for human and animal health, has recently released its financial results for the most recent fiscal period. The company has seen some mixed performance, with a widening of diminishing returns and a decrease in revenue, but also an improvement in earnings per share and a significant reduction in net deficit.
To start, the company experienced a widening of diminishing returns in the most recent fiscal period, with a loss of $0.38 per share compared to $0.12 per share in the same period a year ago. However, there was a promising improvement in earnings per share from the previous reporting season, with a decrease from $0.42 per share to the current figure.
In terms of revenue, Jaguar Health Inc faced a significant decline, with a decrease of 10.698% from $3.15 million to $2.81 million in the corresponding reporting season a year ago. However, sequentially, there was a 5.12% increase from $2.68 million, indicating some progress.

Jaguar Health Inc

Jaguar Health Inc Faces Worsening Losses, with Revenue Plunging by 8% in Q2 2023



In the second quarter of 2023, Jaguar Health Inc encountered a decline in demand, resulting in fading revenue and an increased loss. Losses have widened to $-0.42 per share, and the company witnessed a year-on-year drop in revenue by -8.388% to $2.68 million. This news report will assess the financial performance of Jaguar Health Inc during this period and its outlook for the future.
Financial Performance:
During the preceding reporting season, Jaguar Health Inc achieved a revenue of $1.97 million and a bottom line of $-2.39 per share. However, in the second quarter of 2023, the company reported a net loss of $-12.291 million, which marked a significant increase from $-9.390 million in the same period a year ago.

Jaguar Health Inc

Jaguar Health Inc's First Quarter Earnings Reveals Alarming Widening Deficit, Signaling Trouble Ahead for the Company

As a journalist, I have analyzed the financial results of Jaguar Health Inc for the first quarter of 2023. The company recorded a cumulative net loss of $-43 million during the twelve-month period ending in the first quarter of 2023. This resulted in a negative return on equity (ROE) of -1346.86%. The return on equity has deteriorated compared to the fourth quarter of 2022, where it was at 0. The total ranking has now dropped to 4330, reflecting a significant decline.
Jaguar Health Inc operates in the Major Pharmaceutical Preparations industry, and there are 456 other companies that had a higher return on equity than JAGX. This indicates that the company is not performing as well as its peers in the industry.






 

Jaguar Health Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com